Utility of Alpha-Fetoprotein and Ultrasound in the Diagnosis and Prognosis of Patients with Hepatocellular Liver Cancer
DOI: https://doi.org/10.2147/jmdh.s449276
2024-04-24
Journal of Multidisciplinary Healthcare
Abstract:Dongfang Huang, 1– 3 Jianhuai Zhang, 3 Jianbo Xu, 3 Qiang Niu, 2 Dinghua Zhou 2 1 Department of Hepatobiliary Surgery, Medical College of Soochow University, Suzhou, People's Republic of China; 2 Department of Hepatobiliary Surgery, PLA Rocket Force Characteristic Medical Center, Beijing, People's Republic of China; 3 Department of Hepatobiliary Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, People's Republic of China Correspondence: Dinghua Zhou, Department of Hepatobiliary Surgery, PLA Rocket Force Characteristic Medical Center, No. 16 Xinjiekou Outer Street, Xicheng District, Beijing, 100088, People's Republic of China, Tel +86 010-66343003, Fax +86 010-66343055, Email Objective: To investigate the utility of alpha-fetoprotein (AFP) and ultrasound in the diagnosis and prognosis of patients with hepatocellular liver cancer (HCC). Methods: Using retrospective convenience sampling, 401 patients with HCC who underwent transarterial chemoembolisation at the Department of Oncology of The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University between June 2015 and January 2020 were recruited and assigned to the case group. Simultaneously, patients matched to the case group in terms of gender and age but excluded for HCC were enrolled at a 1:1 ratio and classified as the control group. Relevant parameters were collected from both groups for comparison. Results: Both AFP levels and ultrasound results demonstrated diagnostic value for patients with HCC ( P < 0.05). Their combined use exhibited the highest diagnostic accuracy for the cancer, with an area under the curve of 0.896 (95% confidence interval [CI]: 0.876, 0.923), a sensitivity of 67.65% and a specificity of 91.22%. In terms of overall survival (OS), statistically significant differences in the OS rates were observed between the low-AFP (L-AFP) group and high-AFP (H-AFP) group as well as between the low-tumour-diameter (LTD) group and high-tumour-diameter (HTD) group (81.31% vs 52.22% and 85.11% vs 63.41%, respectively; P < 0.05). Regarding the progression-free survival (PFS), significant differences in the PFS rates were also noted between the L-AFP and H-AFP groups and between the LTD and HTD groups (81.31% vs 52.22% and 85.11% vs 63.41%, respectively; P < 0.05). Conclusion: Ultrasound and AFP display notable distinctions when used in the diagnosis of HCC. The sensitivity of ultrasound as a standalone diagnostic tool surpasses that of AFP alone. However, their combined use results in much higher specificity than the use of either test individually. In addition, both techniques hold predictive value for patients' OS and PFS, enabling timely prognostic assessment. Keywords: alpha-fetoprotein, hepatocellular liver cancer, ultrasound, survival analysis, prognosis Hepatocellular liver cancer (HCC) is the fourth most prevalent tumour and the third leading cause of cancer mortality in China. 1 Furthermore, China accounts for over 50% of new liver cancer cases globally annually, with this percentage steadily increasing. 2 Every year, approximately 360,000 new cases of HCC and 350,000 related deaths occur in China. 3 This clearly underscores the persistent and pressing public health concern posed by HCC in the country. Given the scarcity of liver sources for transplant, the prevailing treatment for liver cancer in China involves resection followed by postoperative chemotherapy despite a relatively high post-surgery recurrence rate. Relevant studies 4 have reported a one-year survival rate of 84.3%, a three-year survival rate of 69.5%, a five-year survival rate of 39.4% and a median survival time of 50.14 months in patients with liver cancer post-surgery. Symptoms of HCC, particularly in its early stages, often lack specificity, leading many patients to seek medical care during the middle to late stages. To improve the early diagnosis rates of HCC, international liver disease prevention, diagnosis and treatment guidelines recommend that high-risk groups, including patients with chronic hepatitis and cirrhosis, undergo liver ultrasonography and serum alpha-fetoprotein (AFP) examinations at least once every six months for early HCC screening. Currently, abdominal ultrasound is used as a routine method for liver cancer examination in hospitals, offering the advantages of affordability, convenience, non-invasiveness and minimal radiation exposure for clinical staff. 5 However, this method can be easily affected by the operator's skill level as well as machine sensitivity, lesion size and patient obesity. 5 Conventional ultrasound has reported accur -Abstract Truncated-
health care sciences & services